However, although TKIs and EGFR-targeting antibodies are frequently used in the clinical treatment of non-small cell lung cancer (NSCLC), EGFR-targeting therapy faces a major challenge because patients often develop innate or acquired drug resistance within a year of starting treatment 6, 7. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.